IgE as adjuvant in tumor vaccination

Cancer and IgE: Introducing the Concept of AllergoOncology

Volumn , Issue , 2010, Pages 215-229

  Nigro, Elisa A ^a   Siccardi, Antonio G ^a   Vangelista, Luca ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84855390024     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-60761-451-7_9     Document Type: Chapter

References (39)

1. Gould HJ, Sutton BJ, Beavil AJ, Beavil RL, McCloskey N, Coker HA, Fear D, Smurthwaite L (2003) The biology of IGE and the basis of allergic disease. Annu Rev Immunol 21:579-628
2. Jensen-Jarolim E, Achatz G, Turner MC, Karagiannis S, Legrand F, Capron M, Penichet ML, Rodríguez JA, Siccardi AG, Vangelista L, Riemer AB, Gould H (2008) AllergoOncology: The role of IgE-mediated allergy in cancer. Allergy 63:1255-1266
3. Moro M, Pelagi M, Fulci G, Paganelli G, Dellabona P, Casorati G, Siccardi AG, Corti A (1997) Tumor cell targeting with antibody-Avidin complexes and biotinylated tumor necrosis factor alpha. Cancer Res 57:1922-1928
4. Gasparri A, Moro M, Curnis F, Sacchi A, Pagano S, Veglia F, Casorati G, Siccardi AG, Dellabona P, Corti A (1999) Tumor pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis factor alpha in mouse models. Cancer Res 59:2917-2923
5. Guidi F, Spagnoli GC, Neri G, Paganelli G, Siccardi AG, Guttinger M (1998) Three-step tumor targeting via biotin-Avidin interaction as a versatile system to elicit T-cell-mediated, non-MHC-restricted cytotoxic activity against neoplastic cells. Int J Cancer 76:443-447
6. GuttingerM, Guidi F, Chinol M, Reali E, Veglia F, Viale G, Paganelli G, Corti A, Siccardi AG (2000) Adoptive immunotherapy by avidin-driven cytotoxic T lymphocyte-tumor bridging. Cancer Res 60:4211-4215
7. Paganelli G, Grana C, Chinol M, Cremonesi M, De Cicco C, De Braud F, Robertson C, Zurrida S, Casadio C, Zoboli S, Siccardi AG, Veronesi U (1999) Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med 26:348-357
8. Siccardi AG, Paganelli G, Pontiroli AE, Pelagi M, Magnani P, Viale G, Faglia G, Fazio F (1996) In vivo imaging of chromogranin A-positive endocrine tumours by three-step monoclonal antibody targeting. Eur J Nucl Med 23:1455-1459
9. Robbins PF, Kantor JA, Salgaller M, Hand PH, Fernsten PD, Schlom J (1991) Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. Cancer Res 51:3657-3662
10. Reali E, Greiner JW, Corti A, Gould HJ, Bottazzoli F, Paganelli G, Schlom J, Siccardi AG (2001) IgEs targeted on tumor cells: Therapeutic activity and potential in the design of tumor vaccines. Cancer Res 61:5517-5522
11. Vangelista L, Soprana E, Cesco-Gaspere M, Mandiola P, Di Lullo G, Fucci RN, Codazzi F, Palini A, Paganelli G, Burrone OR, Siccardi AG (2005) Membrane IgE binds and activates Fc epsilon RI in an antigen-independent manner. J Immunol 174:5602-5611
12. Wittek R, Moss B (1980) Tandem repeats within the inverted terminal repetition of vaccinia virus DNA. Cell 21:277-284
13. Moss B (1996) Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 93:11341-11348
14. Brochier B, Costy F, Pastoret PP (1995) Elimination of fox rabies from Belgium using a recombinant vaccinia-rabies vaccine: An update. Vet Microbiol 46:269-279
15. Nigro EA, Brini AT, Soprana E, Ambrosi A, Dombrowicz D, Siccardi AG, Vangelista L (2009) Antitumor IgE Adjuvanticity: Key Role of FceRI. J Immunol 183:4530-4536
16. Mayr A, Hochstein-Mintzel V, Stickl H (1975) Abstammung, eigenschaften und Verwendung des attenuierten Vaccinia-Stammes MVA. Infection 3:6-16
17. Meyer H, Sutter G, Mayr A (1991) Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 72(Pt5): 1031-1038
18. Sutter G, Moss B (1992) Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA 89:10847-10851
19. Mayr A, Danner K (1978) Vaccination against pox diseases under immunosuppressive conditions. Dev Biol Stand 41:225-234
20. Acres B, Bonnefoy JY (2008) Clinical development of MVA-based therapeutic cancer vaccines. Expert Rev Vaccines 7:889-893
21. Liu M, Acres B, Balloul JM, Bizouarne N, Paul S, Slos P, Squiban P (2004) Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci USA 101(Suppl 2):14567-14571
22. McConkey SJ, Reece WH, Moorthy VS, Webster D, Dunachie S, Butcher G, Vuola JM, Blanchard TJ, Gothard P, Watkins K, Hannan CM, Everaere S, Brown K, Kester KE, Cummings J, Williams J, Heppner DG, Pathan A, Flanagan K, Arulanantham N, Roberts MT, Roy M, Smith GL, Schneider J, Peto T, Sinden RE, Gilbert SC, Hill AV (2003) Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 9:729-735
23. Gilbert SC, Moorthy VS, Andrews L, Pathan AA, McConkey SJ, Vuola JM, Keating SM, Berthoud T, Webster D, McShane H, Hill AV (2006) Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine 24:4554-4561
24. Mwau M, Cebere I, Sutton J, Chikoti P, Winstone N, Wee EG, Beattie T, Chen YH, Dorrell L, McShane H, Schmidt C, Brooks M, Patel S, Roberts J, Conlon C, Rowland-Jones SL, Bwayo JJ, McMichael AJ, Hanke T (2004) A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: Stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 85:911-919
25. Staib C, Drexler I, Ohlmann M, Wintersperger S, Erfle V, Sutter G (2000) Transient host range selection for genetic engineering of modified vaccinia virus Ankara. BioTechniques 28:1137-1142, 1144-1146, 1148
26. Staib C, Lowel M, Erfle V, Sutter G (2003) Improved host range selection for recombinant modified vaccinia virus Ankara. BioTechniques 34:694-696, 698, 700
27. Di Lullo G, Soprana E, Panigada M, Palini A, Erfle V, Staib C, Sutter G, Siccardi AG (2009) Marker gene swapping facilitates recombinant Modified Vaccinia Virus Ankara production by host-range selection. J Virol Methods 156:37-43
28. Dombrowicz D, Flamand V, Brigman KK, Koller BH, Kinet JP (1993) Abolition of anaphylaxis by targeted disruption of the high affinity immunoglobulin E receptor alpha chain gene. Cell 75:969-976
29. Yu P, Kosco-Vilbois M, Richards M, Kohler G, Lamers MC (1994) Negative feedback regulation of IgE synthesis by murine CD23. Nature 369:753-756
30. Benigni F, Zimmermann VS, Hugues S, Caserta S, Basso V, Rivino L, Ingulli E, Malherbe L, Glaichenhaus N, Mondino A (2005) Phenotype and homing of CD4 tumor-specific T-cells is modulated by tumor bulk. J Immunol 175:739-748
31. Rosato A, Zoso A, Milan G, Macino B, Dalla Santa S, Tosello V, Di Carlo E, Musiani P, Whalen RG, Zanovello P (2003) Individual analysis of mice vaccinated against a weakly immunogenic self tumor-specific antigen reveals a correlation between CD8 T-cell response and antitumor efficacy. J Immunol 171:5172-5179
32. Vangelista L (2003) Current progress in the understanding of IgE-Fc epsilon RI interaction. Int Arch Allergy Immunol 131:222-233
33. Venkitaraman AR, Williams GT, Dariavach P, Neuberger MS (1991) The B-cell antigen receptor of the five immunoglobulin classes. Nature 352:777-781
34. Dombrowicz D, Brini AT, Flamand V, Hicks E, Snouwaert JN, Kinet JP, Koller BH (1996) Anaphylaxis mediated through a humanized high affinity IgE receptor. J Immunol 157: 1645-1651
35. Dombrowicz D, Lin S, Flamand V, Brini AT, Koller BH, Kinet JP (1998) Allergy-Associated FcR beta is a molecular amplifier of IgE- and IgG-b in vivo responses. Immunity 8:517-529
36. Kayaba H, Dombrowicz D, Woerly G, Papin JP, Loiseau S, Capron M (2001) Human eosinophils and human high affinity IgE receptor transgenic mouse eosinophils express low levels of high affinity IgE receptor, but release IL-10 upon receptor activation. J Immunol 167:995-1003
37. Kinet JP (1999) The high-Affinity IgE receptor (Fc epsilon RI): From physiology to pathology. Annu Rev Immunol 17:931-972
38. Hodge JW, Higgins J, Schlom J (2009) Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen. Vaccine 27:4475-4482
39. Garman SC, Wurzburg BA, Tarchevskaya SS, Kinet JP, Jardetzky TS (2000) Structure of the Fc fragment of human IgE bound to its high-Affinity receptor Fc epsilonRI alpha. Nature 406:259-266